Zydus Lifesciences' manufacturing plant receives adverse observations in USFDA inspection

24 Apr 2024 , 03:53 PM

Zydus Life shares experienced a decline on Wednesday, April 24, following the company’s announcement regarding observations received from the USFDA for its injectable manufacturing site in Jarod, Gujarat.

The USFDA conducted an inspection of the facility from April 15 to April 23 and issued 10 observations. The company stated that it would collaborate closely with the USFDA to promptly address and respond to the observations.

Additionally, earlier in the week, Zydus Life launched Mirabegron Extended-Release tablets, 25 mg, for the treatment of overactive bladder in the US market.

Mirabegron is prescribed for overactive bladder symptoms such as urge urinary incontinence, urgency, and urinary frequency. The tablet will be manufactured at the company’s formulation manufacturing facility in Ahmedabad SEZ, India.

At the time of writing on April 24, the stock was down by 2.76% at ₹933 apiece.

For feedback and suggestions, write to us at [e-mail]